Curcumin for Radiation Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Thirty Breast Cancer Patients

Ryan, Julie L.; Heckler, Charles E.; Ling, Marilyn N.; Katz, Alan W.; Williams, Jacqueline P.; Pentland, Alice P.; Morrow, Gary R.

doi:10.1667/rr3255.1

Cited by 223 publications

(176 citation statements)

References 49 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…[11][12][13][14][15][16] Curcumin has a long history of use in Ayurvedic medicine treatment for inflammatory conditions 17,18 as it has an ability to inhibit nuclear factor κB. 19 It has been used in the treatment of various skin diseases and conditions, 20 especially wounds, 21 psoriasis, 22,23 radiation-induced dermatitis, 24 allergic dermatitis, 25 and skin cancer. [26][27][28] Although it exhibits favorable biological activities on the skin, some properties of curcumin limit its potential as a therapeutic agent, such as poor water solubility and low bioavailability, 29 resulting in limited skin penetration 30 and poor transport through the stratum corneum.…”

Section: Introductionmentioning

confidence: 99%

Design, characterization, and biological evaluation of curcumin-loaded surfactant-based systems for topical drug delivery

Fonseca-Santos

Santos

Rodero

et al. 2016

IJN

View full text Add to dashboard Cite

From previous studies, it has been found that curcumin exhibits an anti-inflammatory activity and is being used for the treatment of skin disorders; however, it is hydrophobic and has weak penetrating ability, resulting in poor drug transport through the stratum corneum. The aim of this study was to develop liquid crystalline systems for topical administration of curcumin for the treatment of inflammation. These liquid crystalline systems were developed from oleic acid, polyoxypropylene (5) polyoxyethylene (20) cetyl alcohol, and water as the surfactant, oil phase, and aqueous phase, respectively. These systems were characterized, and polarized light microscopy showed anisotropy with lamellar mesophases (Formulation 1) and hexagonal mesophases (Formulations 2 and 3), which were confirmed by the peak ratio measured using small-angle X-ray scattering. In addition, rheological tests revealed that the formulations exhibited gel-like behavior (G′>G″), as evidenced by the increased G′ values that indicate structured systems. Texture profile analysis showed that hexagonal mesophases have high values of hardness, adhesiveness, and compressibility, which indicate structured systems. In vitro studies on bioadhesion revealed that the hexagonal mesophases increased the bioadhesiveness of the systems to the skin of the pig ear. An in vivo inflammation experiment showed that the curcumin-loaded hexagonal mesophase exhibited an anti-inflammatory activity as compared to the positive control (dexamethasone). The results suggest that this system has a potential to be used as a bioadhesive vehicle for the topical administration of curcumin. Therefore, it is possible to conclude that these systems can be used for the optimization of drug delivery systems to the skin.

show abstract

Section: Introductionmentioning

confidence: 99%

Design, characterization, and biological evaluation of curcumin-loaded surfactant-based systems for topical drug delivery

Fonseca-Santos

Santos

Rodero

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…The data from NHP for cutaneous effects are limited (Williams et al 2010). There are several countermeasures, such as PrC-210 (Peebles et al 2012), Fibroblast growth factor-P (Zhang et al 2011), Pravastatin (Holler et al 2009), Plerixafor (Kim et al 2012), and curcumin (Okunieff et al 2006;Ryan et al 2013), that have demonstrated efficacy for cutaneous radiation syndrome in different animal models. A summary of the main sub-syndromes and their symptoms is provided in Table 1.…”

Section: Cutaneous Syndromementioning

confidence: 99%

A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures

Singh

Seed²

2017

International Journal of Radiation Biology

142

103

View full text Add to dashboard Cite

Purpose: The increasing global risk of nuclear and radiological accidents or attacks has driven renewed research interest in developing medical countermeasures to potentially injurious exposures to acute irradiation. Clinical symptoms and signs of a developing acute radiation injury, i.e. the acute radiation syndrome, are grouped into three sub-syndromes named after the dominant organ system affected, namely the hematopoietic, gastrointestinal, and neurovascular systems. The availability of safe and effective countermeasures against the above threats currently represents a significant unmet medical need. This is the first article within a three-part series covering the nature of the radiation subsyndromes, various animal models for radiation countermeasure development, and the agents currently approved by the United States Food and Drug Administration for countering the medical consequences of several of these prominent radiation exposure-associated syndromes. Conclusions: From the U.S. and global perspectives, biomedical research concerning medical countermeasure development is quite robust, largely due to increased government funding following the 9/11 incidence and subsequent rise of terrorist-associated threats. A wide spectrum of radiation countermeasures for specific types of radiation injuries is currently under investigation. However, only a few radiation countermeasures have been fully approved by regulatory agencies for human use during radiological/nuclear contingencies. Additional research effort, with additional funding, clearly will be needed in order to fill this significant, unmet medical health problem. ARTICLE HISTORY

show abstract

“…Radioprotektivní účinek kurkuminu byl potvrzen i při jeho systémovém podá-vání 30 ženám, u kterých byla indikována radioterapie pro karcinom prsu. Při dávce 6 g kurkuminu per os denně měly pa cientky o téměř 60 % nižší incidenci vlhkých deskvamací oproti kontrolní skupině, došlo tedy ke snížení závažnosti radiační dermatitidy [48].…”

Section: Závěrunclassified

“…Počet pacientů Dávka a doba užívání Výsledek Reference orální mukositida při radioterapii pro karcinom hlavy a krku 80 6× denně ve formě kloktadla, 7 týdnů oddálení nástupu, snížení stupně závažnosti orální mukositidy; menší počet přerušení onkologické léčby; menší změny ve váze pacientů [47] radiační dermatitida při radioterapii pro karcinom prsu 30 6 g denně p.o., po dobu radioterapie snížení závažnosti radiační dermatitidy [48] anorexie u onkologických pacientů 17 směs 1 g kurkuminu a 1 g zázvoru 2× denně, 1 ml tinktury z hořce žlutého 3× denně, 2 týdny bez efektu, špatná tolerance [49] Zařazení kurkuminu do standardní léčby onkologického pa cienta zatím není možné, stejně jako přesnější doporučení o jeho kombinování s další onkologickou léčbou. Nicméně výsledky dostupných studií naznačují, že kurkumin má potenciál stát se doplňkem stravy nebo léčivem, které může dílem při-spět k boji proti nádorovému onemocnění a též pomoci pa cientovi zvládat NÚ onkologické léčby.…”

Section: Diagnózaunclassified

Curcumine (Turmeric – Curcuma longa) as a Supportive Phytotherapeutic Treatment in Oncology

Frassová¹

2018

Klin Onkol

View full text Add to dashboard Cite

Východiska: Kurkumovník dlouhý (Curcuma longa) je rostlina, která je známá především jako součást kari koření. Hlavní obsahovou látkou zodpovídající za většinu bio logických účinků je polyfenol kurkumin. Cíl: Tato přehledová práce má za cíl poskytnout ucelený obraz o výsledcích studií, které se věnují léčebnému využití kurkuminu v onkologii. Preklinické studie poskytují informace o mechanizmech účinku a případné toxicitě kurkuminu. Klinické studie jsou zatím zaměřeny především na bezpečnost, farmakokinetiku a stanovení optimální dávky kurkuminu, narůstá ovšem i počet studií, které hodnotí protinádorové a onkopreventivní účinky kurkuminu, případně podpůrný úči-nek při řešení nežádoucích účinků chemoterapeutik a radioterapie. Jejich výsledky jsou optimistické a povzbuzují k dalšímu výzkumu. Největším problémem léčby kurkuminem je jeho nízká biologická dostupnost, ze které vyplývá nutnost použití vysokých dávek. Z tohoto důvodu se jeví jako nejvýhodnější využít lokálního působení kurkuminu ve střevě, na sliznicích nebo na kůži, tedy tam, kde odpadá nutnost systémového působení. Současné poznatky vyzdvihují zejména bezpečnost kurkuminu, a to až do dávek několika gramů. Dle dostupných informací lze užívání kurkuminu jako doplňku stravy doporučit lidem, kteří mají zvýšené riziko onkologického onemocnění, jako jsou např. silní kuřáci, nebo pa cientům s prekancerózními lézemi. Vzhledem k již zmíněné bezpečnosti je možno kurkumin doporučit i onkologickým pa cientům, kteří vyžadují přírodní léčbu. Klíčová slovafytoterapie -interakce -nádorová onemocnění -nežádoucí účinky -kurkumin -kurkumaCurcuma longa SummaryBackground: Turmeric (Curcuma longa) is mainly known as a constituent of curry spice. The main active ingredient, responsible for most of its bio logical effects, is the polyphenol curcumin. Aim: This review aims to provide a comprehensive overview of studies evaluat ing the benefits of therapeutic curcumin use in oncology. Preclinical studies provide information on the mechanism of action and potential toxicity of curcumin. Clinical studies have so far focused mainly on safety, pharmacokinetics, and determination of the optimal dose of curcumin. However, there are a grow ing number of trials evaluat ing the anti-tumor and oncopreventive effects of curcumin and its effect in alleviat ing the adverse effects of chemotherapeutics and radiother apy. So far, the results have been optimistic and should encourage further research. The main problem associated with curcumin treatment is its low oral bio availability, which means it must administrated at high doses to be effective. Therefore, curcumin is more appropriate as a local treatment for areas such as the intestine, mucous membrane, or the skin, where there is no need for a strong systemic effect. Curcumin has a good safety profile when used up to several grams. Curcumin can also be used as a food supplement for people at increased risk of oncological dis ease, such as heavy smokers or those with pre-cancerous lesions. Due to its good safety profile, curcumin can be r...

show abstract

Curcumin for Radiation Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Thirty Breast Cancer Patients

Cited by 223 publications

References 49 publications

Design, characterization, and biological evaluation of curcumin-loaded surfactant-based systems for topical drug delivery

Design, characterization, and biological evaluation of curcumin-loaded surfactant-based systems for topical drug delivery

A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures

Curcumine (Turmeric – Curcuma longa) as a Supportive Phytotherapeutic Treatment in Oncology

Contact Info

Product

Resources

About